Pioglitazone restores endothelial function patients with type 2 diabetes treated with insulin

Metabolic Syndrome and Related Disorders

Volumn 4, Issue 3, 2006, Pages 179-184

  Asnani, Sunil ^a,b,c   Kunhiraman, Biju ^a   Jawa, Ali ^a   Akers, Donald ^a   Lumpkin, David ^a   Fonseca, Vivian ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD FLOW; BLOOD VESSEL FUNCTION; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TREND STUDY; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 33750364401     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2006.4.179     Document Type: Article

References (24)

1. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281: 1291-1297.
2. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
3. Fonseca V, Desouza C, Asnani S, et al. Nontraditional risk factors for cardiovascular disease in diabetes. Endocrine Rev 2004;25:153-175.
4. Saito I, Folsom AR, Brancati FL, et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000;133:81-91.
5. Kunhiraman B, Jawa A, Fonseca VA. Potential cardiovascular benefits of insulin sensitizers. Endocrinol Metab Clin North Am 2005;34:117-135.
6. Mohanty P, Aljada A, Ghanim H, et al. Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein (MCP-1):evidence of a potent anti-inflammatory effect. Diabetes 2001;50:A68.
7. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metab Clin Exp 2003;52:173-180.
8. Desouza C, Parulkar A, Lumpkin D, et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes Diabetes Care 2002;25:1336-1339.
9. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338: 867-872.
10. Vita JA, Keaney Jr JF. Endothelial function: a barometer for cardiovascular risk? Circulation 2002;106: 640-642.
11. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906.
12. Kuvin JT, Karas RH. Clinical utility of endothelial function testing: ready for prime time? Circulation 2003;107:3243-3247.
13. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97: 1695-1701.
14. Baron AD, Steinberg HO. Endothelial function, insulin sensitivity, and hypertension. Circulation 1997; 96:725-726.
15. Steinberg HO, Chaker H, Learning R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-2610.
16. Steinberg HO, Paradisi G, Hook G, et al. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000;49:1231-1238.
17. Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. JCEM 2004;89:4312-4319.
18. Bagg W, Whalley GA, Gamble G, et al. Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Intern Med J 2001;31: 322-328.
19. Gaenzer H, Neumayr G, Marschang P, et al. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am J Cardiol 2002;89:431-434.
20. Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004;27:484-490.
21. Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2000;36:430-435.
22. Kruszynska YT, Yu JG, Olefsky JM, et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000;49:633-639.
23. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-2499.
24. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289.